Evaluation of IDH1G105 polymorphism as prognostic marker in intermediate-risk AML

Annals of Hematology
Annette FasanS Schnittger

Abstract

Germline polymorphisms in genes mutated in acute myeloid leukemia (AML) may have prognostic impact. Therefore, the relevance of the polymorphism IDH1G105 (IDH1105(GGT) minor allele) was evaluated in the context of concomitant molecular mutations in a cohort of 507 AML cases with intermediate-risk cytogenetics. In addition, a cohort of 475 healthy controls was analyzed for this polymorphism. IDH1105(GGT) minor allele was found in 10 % of AML patients and 9 % of healthy controls. While no differences were seen with regard to cytomorphology or cytogenetics, immunophenotyping revealed significantly reduced expression of the progenitor marker CD34 in AML cases harboring IDH1105(GGT) minor allele. Cases with IDH1105(GGT) minor allele as compared to those with the IDH1105(GGC) major allele had significantly longer event-free survival (EFS) (median 16 vs 11 months, p = 0.013) which was most pronounced in the age group >60 years (median 14 vs 9 months, p = 0.007) and in the NPM1 mutated/FLT3-ITD/FLT3wt ratio <0.5 group (median 61 vs 13 months, p = 0.012). However, this association is not independent of other prognostic parameters, and we conclude that IDH1105(GGT) minor allele has to be considered in the context of the genetic backgroun...Continue Reading

References

Sep 13, 1996·Science·N Risch, K Merikangas
Oct 25, 1996·Science·E S Lander
Dec 31, 1997·Science·F S CollinsA Charkravarti
Aug 7, 2002·Current Oncology Reports·Claudia Schoch, Torsten Haferlach
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Jan 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stefan FröhlingKonstanze Döhner
Jan 22, 2005·The New England Journal of Medicine·Brunangelo FaliniUNKNOWN GIMEMA Acute Leukemia Working Party
Jul 21, 2005·Das Gesundheitswesen·R HolleUNKNOWN MONICA/KORA Study Group
Jul 21, 2005·Das Gesundheitswesen·H-E WichmannUNKNOWN MONICA/KORA Study Group
Jan 26, 2006·Blood·Ulrike BacherSusanne Schnittger
Dec 23, 2006·Science·Chava Kimchi-SarfatyMichael M Gottesman
Jun 15, 2007·Pharmacogenomics·Zuben E SaunaMichael M Gottesman
Aug 30, 2008·Journal of Molecular Biology·Chung-Jung TsaiRuth Nussinov
Feb 21, 2009·The New England Journal of Medicine·Hai YanDarell D Bigner
Aug 7, 2009·The New England Journal of Medicine·Elaine R MardisTimothy J Ley
Nov 26, 2009·Nature·Lenny DangShinsan M Su
Dec 30, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Frederik DammJürgen Krauter
Apr 7, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Katharina WagnerJürgen Krauter
Jul 21, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alexander KohlmannTorsten Haferlach

❮ Previous
Next ❯

Citations

Jul 7, 2016·Pharmacogenomics·Juan Eduardo Megías-VericatSalvador F Aliño

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.